Assessment of Prescribing Practice of Anti-Hypertensive Medications in a Sample of Iraqi Patients with Diabetes
,
 
 
 
More details
Hide details
1
Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, University of Kufa, Najaf Governorate, Iraq, Iraq
 
 
Submission date: 2023-12-11
 
 
Final revision date: 2024-08-11
 
 
Acceptance date: 2024-11-12
 
 
Publication date: 2024-12-30
 
 
Corresponding author
Amina Jabri   

Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, University of Kufa, Najaf Governorate, Iraq, Iraq
 
 
Wiadomości Lekarskie 2024;77(12):2419-2425
 
KEYWORDS
TOPICS
ABSTRACT
Aim:
Background: Hypertension and diabetes cause most cardiovascular deaths and morbidity, and the coexistence of these disorders requires attention and reasonable care. Studies on drug usage offer valuable insights into healthcare systems, providing an avenue to evaluate and enhance current practices. Diabetic individuals are twice as likely to develop hypertension as non-diabetics of equivalent age. Blood pressure (BP) regulation holds the key to mitigating both micro- and macrovascular complications. Aims: This research aims to comprehensively assess the prescribing practices of anti-hypertensive medications in a sample of Iraqi patients with diabetes. Specifically, exploring medication types and classes, adherence to clinical guidelines for managing hypertension in the context of diabetes, and factors influencing prescribing decisions.

Material and methods:
Materials and Methods: This descriptive cross-sectional retrospective study investigates medication usage in an outpatient clinic in Najaf, Iraq, utilizing systematic sampling. A total of 157 prescriptions from hypertensive outpatients aged 18 and above with comorbid diabetes were randomly selected.

Results:
Results: In our study, diabetic hypertensive patients were found to be administered antihypertensive medicines. The usage patterns revealed that a substantial proportion relied on CCBs (48.4%), followed by ARBs (34.4%), ACEIs (32.5%) and Diuretics (32.5%). Notably, single-drug therapy with CCB was more common than multiple-drug therapy among diabetic hypertensive patients in this investigation.

Conclusions:
Conclusion: Our findings indicate that CCBs were the most frequently used group of drugs. Diabetes-specific problems are more likely in hypertension patients with diabetes; thus, prompt diagnosis and treatment are needed to decrease macro and micro-vascular consequences.
REFERENCES (31)
1.
Care D, Suppl SS. Classification and Diagnosis of Diabetes : Standards of Medical Care in Diabetes. 2021;44: 15-33. DOI: 10.2337/dc21-S002.
 
2.
Grillo A, Salvi L, Coruzzi P et al. Sodium Intake and Hypertension. 2019;11(9):1970. DOI: 10.3390/nu11091970.
 
3.
World Health Organization. Noncommunicable diseases. WHO Regional Office for the Eastern Mediterranean [Internet]. Available from: https://www.emro.who.int/iraq/....
 
4.
Es C, Pj S, Sambathkumar R. Comparison of Antihypertensive Combination Therapy and Glycemic Control in Diabetic Hypertensive Patients. J. Pharm. Sci. & Res. 2019;11(7):2634-2638.
 
5.
Stanciu S, Rusu R, Dinu E et al. Links between metabolic syndrome and hypertension: The relationship with the current antidiabetic drugs. Metabolites. 2023;13(1):87. DOI:10.3390/metabo13010087.
 
6.
Petrie JR, Guzik TJ, Touyz RM. Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms. Can J Cardiol. 2018;34(5):575-584. DOI:10.1016/j.cjca.2017.12.005.
 
7.
Jang S, Han E, Kang C et al. Research in Social and Administrative Pharmacy Assessment of a medication management program targeting hypertension and diabetes patients : Impact on medication adherence. Res. Soc. Adm. Pharm. 2021;17(2):419-427. DOI: 10.1016/j.sapharm.2020.03.002.
 
8.
Kim HJ, Kim K. Blood pressure target in type 2 diabetes mellitus. Diabetes Metab J. 2022;46(5):667-674. DOI:10.4093/dmj.2022.0215.
 
9.
Kjeldsen SE, Os I, Nilsson PM. Does intensive glucose control cancel out benefits of systolic blood pressure target <120 mm Hg in patients with diabetes mellitus participating in ACCORD? Hypertension. 2018;72(2):291-293. DOI:10.1161/hypertensionaha.118.11455.
 
10.
Kearney PM, Whelton M, Reynolds K et al. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365(9455):217-223. DOI:10.1016/s0140-6736(05)17741-1.
 
11.
Whalen KL, Stewart RD. Pharmacologic management of hypertension in patients with diabetes. Am. Fam. Physician. 2008;78(11):1277-1282.
 
12.
Banerjee D, Winocour P, Chowdhury TA et al. Management of hypertension and renin-angiotensin-aldosterone system blockade in adults with diabetic kidney disease: Association of British Clinical Diabetologists and the Renal Association UK guideline update 2021. BMC Nephrol. 2022;23(1):1-31. DOI: 10.1186/s12882-021-02587-5.
 
13.
Yamout H, Lazich I, Bakris GL. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease. Adv Chronic Kidney Dis. 2014;21(3):281-286. DOI: 10.1053/j.ackd.2014.03.005.
 
14.
Hiroi S, Shimasaki Y, Kikuchi T et al. Analysis of second- and third-line antihypertensive treatments after initial therapy with an angiotensin II receptor blocker using real-world Japanese data. Nat. Publ. Gr. 2016;5:1–6. DOI: 10.1038/hr.2016.96.
 
15.
Vargas-Uricoechea H, Cáceres-Acosta MF. Control of blood pressure and cardiovascular outcomes in type 2 diabetes. Open Med. 2018;13(1):304-323. DOI:10.1515/med-2018-0048.
 
16.
Ferrannini E, Cushman WC. Diabetes and hypertension: The bad companions. Lancet. 2012;380(9841):601-610. DOI:10.1016/s0140-6736(12)60987-8.
 
17.
Tobe SW, Gilbert RE, Jones C et al. 2018 Clinical Practice Guidelines- Treatment of Hypertension. Can. J. Diabetes. 2018;42:S186-S189. DOI:10.1016/j.jcjd.2017.10.011.
 
18.
Whelton PK, Barzilay J, Cushman WC. Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ACC Curr J Rev. 2005;14(9):24. DOI: 10.1016/j.accreview.2005.08.200.
 
19.
Brook RD, Rajagopalan S, Patel S et al. Prior medications and the cardiovascular benefits from combination angiotensin-converting enzyme inhibition plus calcium channel blockade among high-risk hypertensive patients. J Am Heart Assoc. 2018;7(1):e006940. DOI:10.1161/jaha.117.006940.
 
20.
Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. DOI:10.1093/eurheartj/ehy339.
 
21.
Whelton PK, Carey RM, Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. J Am Coll Cardiol. 2018;71(19). DOI: 10.1016/j.jacc.2017.11.006.
 
22.
Heidari B, Avenatti E, Nasir K. Pharmacotherapy for essential hypertension: A brief review. Methodist DeBakey Cardiovasc J. 2022;18(5):5-16. DOI:10.14797/mdcvj.1175.
 
23.
Chu CD, Garimella PS, Wilson FP et al. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use among hypertensive US adults with albuminuria. Hypertension. 2021;77(1):94-102. DOI:10.1161/hypertensionaha.120.16281.
 
24.
American Diabetes Association. Standards of medical care in diabetes—2022. Diabetes Care. 2022;45(Suppl 1). DOI:10.2337/dc22-S008.
 
25.
Alavudeen SS, Alakhali KM, Ansari SM et al. Prescribing pattern of antihypertensive drugs in diabetic patients of Southern Province, Kingdom of Saudi Arabia. Ars Pharm. 2015;56(2):109-14.
 
26.
Elenchezhiyan V, Swathi D, Kumar DR et al. Study of prescribing pattern of antihypertensive drugs in diabetic patients in a tertiary care centre, Vizianagaram, India. Int J Basic Clin Pharmacol. 2019;8(6):1192. DOI:10.18203/2319-2003.ijbcp20192183.
 
27.
Anantha Babu K. Assessment of efficacy of amlodipine with cilnidipine in hypertensive patients: a comparative study. Int J Contemp Med Res. 2017;4(4):956-958.
 
28.
Dharapur P, Patil K. A comparative study of the efficacy of cilnidipine and amlodipine used for the treatment of hypertension at tertiary health-care center. Natl J Physiol Pharm Pharmacol. 2019;9(0): 454-458. DOI:10.5455/njppp.2019.9.0206726032019.
 
29.
Marinier K, Deltour N, Macouillard P et al. Effectiveness of two-drug therapy versus monotherapy as initial regimen in hypertension: A propensity score-matched cohort study in the UK Clinical Practice Research Datalink. Pharmacoepidemiol Drug Saf. 2019;28(12):1572-1582. DOI:10.1002/pds.4884.
 
30.
Dhanaraj E, Reddy PS, Reddy YJ et al. Prescription pattern of antihypertensive agents in T2DM patients visiting Tertiary Care Centre in North India. Int J Hypertens. 2012;2012:1-9. DOI:10.1155/2012/520915.
 
31.
Dahal P, Bhattarai A, Shah SK et al. Assessment of prescription patterns in hypertensive and diabetic patients visiting private tertiary care hospital of Dharan Municipality, Nepal. Sunsari Tech Coll J. 2016;2(1):44-47. DOI:10.3126/stcj. v2i1.14798.
 
eISSN:2719-342X
ISSN:0043-5147
Journals System - logo
Scroll to top